Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Biomimetic MXene Nanoplatforms for Targeted Combination Therapy of Triple-Negative Breast Cancer

Ziel

"Triple-Negative Breast Cancer (TNBC) remains one of the most challenging subtypes of oncology due to its high metastatic potential, lack of targeted receptors, and rapid development of drug resistance. The BioMIX project proposes a disruptive solution: a ""stealth"" biomimetic nanoplatform designed to bypass the immune system and deliver a potent combination of chemotherapy, gene therapy, and sonodynamic therapy (SDT) directly to the tumor site. The core of the BioMIX technology is a two-dimensional Ti3C2 MXene nanosheet, which serves as a structural scaffold and a high-efficiency sonosensitizer. This core is functionalized with a pH-responsive polydopamine shell to entrap Doxorubicin and a cationic layer to complex anti-MDR1 siRNA. To achieve superior targeting, the construct is ""camouflaged"" with a hybrid membrane fused from TNBC cells and macrophages, further enhanced with iRGD peptides for deep-tissue penetration. Upon reaching the tumor, low-intensity ultrasound is applied to trigger localized hyperthermia and reactive oxygen species (ROS) generation, causing controlled drug release and inducing targeted cancer cell apoptosis. As an MSCA Staff Exchange action, BioMIX is built on a highly interdisciplinary consortium of 13 international partners across the academic and industrial sectors. The project is structured to facilitate more than 200 person-months of knowledge transfer, conveying critical expertise in 2D materials science, microfluidic manufacturing, and preclinical oncology research. By integrating ""Tumor-on-a-Chip"" validation and in vivo efficacy studies, BioMIX aims to establish a clinically translatable framework for targeted nanomedicine while reducing the systemic side effects (such as cardiotoxicity) of conventional chemotherapy. The project’s outcomes will strengthen European leadership in nanobiotechnology and provide a scalable framework for the next generation of biomimetic therapeutic vehicles aligned with Europe’s Beating Cancer Plan."

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-TMA-MSCA-SE - HORIZON TMA MSCA Staff Exchanges

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-MSCA-2026-SE-01

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

LATVIJAS UNIVERSITATE
Netto-EU-Beitrag
€ 155 100,00
Gesamtkosten
Keine Daten

Beteiligte (10)

Partner (2)